Examination of HER3 targeting in cancer using monoclonal antibodies

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2015-01-06

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/pnas.1423645112PMID 25564668PMCID PMC4311849
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The E3 ubiquitin ligase NEDD4 negatively regulates HER3/ErbB3 level and signaling

  2014cited by this paper
• Associate editor: B. TeicherHER3, serious partner in crime: Therapeutic approaches and potential biomarkers for effect of HER3-targeting

  2014cited by this paper
• HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models

  2014cited by this paper
• Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR

  2013influential reference
• Oncogenic ERBB3 mutations in human cancers.

  2013cited by this paper
• Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.

  2013cited by this paper
• Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)

  2013cited by this paper
• Proof-of-concept study of Sym004, an anti-EGFR monoclonal antibody (mAb) mixture, in patients (pts) with anti-EGFR mab-refractory KRAS wild-type (wt) metastatic colorectal cancer (mCRC).

  2013cited by this paper
• Sym004, a novel strategy to target EGFR with an antibody mixture, in patients with advanced SCCHN progressing after anti-EGFR monoclonal antibody: A proof of concept study.

  2013cited by this paper
• The oncoprotein ErbB3 is endocytosed in the absence of added ligand in a clathrin-dependent manner.

  2012cited by this paper
• Advances in Targeting HER3 as an Anticancer Therapy

  2012cited by this paper
• The promise of anti-ErbB3 monoclonals as new cancer therapeutics

  2012cited by this paper
• Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase

  2011cited by this paper
• Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy.

  2010cited by this paper
• An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells.

  2010cited by this paper
• Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments

  2010cited by this paper
• ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation

  2010cited by this paper
• EGFR Signaling and Drug Discovery

  2010cited by this paper
• Mechanisms of resistance to HER family targeting antibodies.

  2010cited by this paper
• Roles for growth factors in cancer progression.

  2010cited by this paper
• Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis

  2009influential reference
• Insulin-Like Growth Factor-1 Receptor Inhibition Induces a Resistance Mechanism via the Epidermal Growth Factor Receptor/HER3/AKT Signaling Pathway: Rational Basis for Cotargeting Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor in Hepatocellular Carcinoma

  2009cited by this paper
• Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells.

  2009cited by this paper
• Interaction of antibodies with ErbB receptor extracellular regions.

  2009cited by this paper
• Novel anticancer targets: revisiting ERBB2 and discovering ERBB3

  2009cited by this paper
• Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.

  2009cited by this paper
• Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

  2008cited by this paper
• EGFR family: Structure physiology signalling and therapeutic targets†

  2008cited by this paper
• ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis.

  2008cited by this paper
• Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.

  2007cited by this paper
• Neuregulin-Induced ErbB3 Downregulation Is Mediated by a Protein Stability Cascade Involving the E3 Ubiquitin Ligase Nrdp1

  2007cited by this paper
• Cancer therapeutic antibodies come of age: Targeting minimal residual disease

  2007cited by this paper
• Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab.

  2007cited by this paper
• Ligand-induced Dimer-Tetramer Transition during the Activation of the Cell Surface Epidermal Growth Factor Receptor-A Multidimensional Microscopy Analysis*

  2005cited by this paper
• Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy.

  2005influential reference
• Grb2 regulates internalization of EGF receptors through clathrin-coated pits.

  2003cited by this paper
• Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha.

  2002cited by this paper
• A mutant EGF‐receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling

  2002cited by this paper
• Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo.

  2002cited by this paper
• Untangling the ErbB signalling network

  2001cited by this paper
• Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1.

  1999cited by this paper
• Alternative Intracellular Routing of ErbB Receptors May Determine Signaling Potency*

  1998cited by this paper
• An Immunological Approach Reveals Biological Differences between the Two NDF/Heregulin Receptors, ErbB-3 and ErbB-4 (*)

  1996influential reference
• Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies.

  1992cited by this paper
• Localization of a major receptor-binding domain for epidermal growth factor by affinity labeling

  1988cited by this paper
• Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo.

  1988cited by this paper

• CircSETD3 interrupts the bidirectional positive feedback of ErbB3 and Akt by sponging miR-4667-5p to inhibit colorectal cancer progression and cetuximab resistance.

  2025cites this paper
• DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer

  2024cites this paper
• Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer

  2023cites this paper
• HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of Cancer

  2023cites this paper
• Transcriptional landscape of DTP-DTEP transition reveals DUSP6 as a driver of HER2 inhibitor tolerance via Neuregulin/HER3 axis

  2023cites this paper
• Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans

  2022cites this paper
• HER3 in cancer: from the bench to the bedside

  2022cites this paper
• Differential tumor inhibitory effects induced by HER3 extracellular subdomain-specific mouse monoclonal antibodies

  2022cites this paper
• Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer

  2021cites this paper
• Targeting ErbB3 Receptor in Cancer with Inhibitory Antibodies from Llama

  2021cites this paper
• Met–HER3 crosstalk supports proliferation via MPZL3 in MET-amplified cancer cells

  2021cites this paper
• Nanobodies for Medical Imaging: About Ready for Prime Time?

  2021cites this paper
• Thirty Years of HER3: From Basic Biology to Therapeutic Interventions

  2021cites this paper
• Inhibitory Effect of Polyclonal Antibodies Against HER3 Extracellular Subdomains on Breast Cancer Cell Lines

  2020cites this paper
• Antibodies and their applications

  2020cites this paper
• Novel functional anti-HER3 monoclonal antibodies with potent anti-cancer effects on various human epithelial cancers

  2020cites this paper
• Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor

  2020cites this paper
• [Bacterial expression of 183-227aa region of HER3 extracellular domain I and preparation and identification of its polyclonal antibodies].

  2020cites this paper
• Anticancer therapeutics: a brief account on wide refinements.

  2020cites this paper
• ITCH-dependent proteasomal degradation of c-FLIP induced by the anti-HER3 antibody 9F7-F11 promotes DR5/caspase 8-mediated apoptosis of tumor cells

  2019cites this paper
• Targeted Delivery to Tumors: Multidirectional Strategies to Improve Treatment Efficiency

  2019cites this paper
• ENGINEERED MULTIVALENCY FOR ENHANCED AFFIBODY-BASED HER3 CANCER THERAPY

  2018cites this paper
• A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways

  2018cites this paper
• Gene networks in basal cell carcinoma of the eyelid, analyzed using gene expression profiling.

  2018cites this paper
• HER3 as a Therapeutic Target in Cancer

  2017cites this paper
• Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer Cells.

  2017cites this paper
• Chapter 2 – Kinases

  2017cites this paper
• ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1)

  2017cites this paper
• Chapter 25 – Afatinib

  2017cites this paper
• Chapter 7 – Erlotinib

  2017cites this paper
• Chapter 6 – Gefitinib

  2017cites this paper
• A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells

  2016cites this paper
• The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation

  2016cites this paper
• Targeting the EGF/HER Ligand-Receptor System in Cancer.

  2016cites this paper
• Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3

  2016cites this paper
• Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti‐cancer antibodies: IUPHAR Review 18

  2016cites this paper
• HER3 expression is correlated to distally located and low-grade colon cancer

  2016cites this paper
• The ErbB2 receptor in gastric cancer: the quick-change artist

  2015cites this paper
• Oligoclonal antibodies to target the ErbB family

  2015cites this paper
• HER-3 targeting alters the dimerization pattern of ErbB protein family members in breast carcinomas

  2015cites this paper
• Novel HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells

  2015cites this paper
• NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies

  2015cites this paper
• HER3 over-expression and overall survival in gastrointestinal cancers

  2015cites this paper
• ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas.

  2015cites this paper
• [The HER3/ERBB3 receptor: the dark side of the ERBB planet].

  2015cites this paper
• Characterizing the Role of Protein Tyrosine Kinase 7 (PTK7) in Cancer Development and Cellular Fitness

  2015cites this paper
• ERBB3 is required for tumor promotion in a mouse model of skin carcinogenesis

  2015cites this paper
• Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer

  2015cites this paper